Ucb Biopharma Sprl

Novartis Ag

Boehringer Ingelheim International Gmbh

Alexander Heifetz

Laura Gleave

Zhaoning Zhu

John Robert Porter

Daniel Christopher Brookings

Julien Alistair Brown

Victoria Elizabeth Jackson

Matthew Duncan Selby

Jonathan Bentley

James Madden

Craig Johnstone

Thomas Paul Cain

Deborah Leigh

Mark G Bock

Klaus Rudolf

Leo Thomas

Dirk Stenkamp

Stefan Scheuerer

Boris Kroeplien

Martin Clive Hutchings

James Andrew Johnson

Bernd Nosse

Heather Tye

James Thomas Reuberson

Marcus Schindler

Fabien Claude Lecomte

Helen Tracey Horsley

Martin Alexander Lowe

Joanna Rachel Quincey

Michael Alan Shaw

Anne Marie Foley

Ellen Olivia Gallimore

Juergen Prestle

Praful Tulshi Chovatia

Stephan-Georg Mueller

David Willows

Ali Raoof

Richard Law

Jonathan Hargrave

Florence Eustache

Jennifer Ruth Dod

Praful Chovatia

Thomas Cain

Jonathan Mark Bentley

Oliver Barker

Christopher John Brown

Sarah Emily Richardson

Anthony John Richardson

Laura Claire Reed

Natacha Prevost

Laura Jane Gleave

Christoper John Brown

A series of imidazo[1,2-a]pyrazine derivatives, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. The imidazo[1,2-a]pyrazine derivatives of the disclosure are of general formula 

Substituted imidazo[1,2-a]pyrazines as TNF activity modulators

The present invention relates to compounds defined by formula I wherein the groups X, Y, W and Rto Rare defined as in claim, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 

Imidazopyridine derivatives as modulators of TNF activity

The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of chronic pain.

Triazine-oxadiazoles

Growing community of inventors

Abingdon, United Kingdom

Alexander Heifetz